This category includes patients who discontinued pemetrexed, a platinum-based drug, and pembrolizumab or placebo because of an adverse event at any time and patients who discontinued pemetrexed and pembrolizumab or placebo for an adverse event after completing four cycles of a platinum-based drug.â€¡